Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.62%GBPCHF+0.52%AUDCHF+0.43%GBPTRY+0.41%NZDCHF+0.41%USDCAD-0.40%EURCAD-0.35%GBPHKD+0.32%CADJPY+0.32%GBPUSD+0.31%GBPMXN-0.28%USDTRY+0.28%AUDSGD+0.27%CHFJPY-0.27%EURCHF+0.27%NZDSGD+0.25%NZDUSD+0.24%AUDUSD+0.23%GBPJPY+0.22%EURGBP-0.22%USDNOK-0.21%NZDCAD-0.20%USDCHF+0.20%GBPSGD+0.19%NZDMXN+0.18%AUDCAD-0.18%USDZAR-0.17%USDILS+0.16%EURSGD+0.16%USDPLN-0.16%USDSEK-0.16%CHFSGD+0.15%AUDJPY+0.15%NZDJPY+0.14%EURAUD-0.13%SGDJPY-0.13%NOKJPY+0.12%EURNZD-0.12%CHFNOK-0.11%AUDDKK+0.11%EURHKD+0.11%USDDKK-0.11%EURNOK-0.10%GBPAUD+0.09%USDTHB+0.09%GBPCAD-0.09%EURCNH+0.08%PLNJPY+0.08%EURUSD+0.07%USDJPY-0.07%GBPNZD+0.07%CHFSEK-0.06%EURZAR-0.06%USDSGD+0.05%EURPLN-0.05%EURSEK-0.05%USDCOP-0.04%GBPZAR-0.03%USDCNH-0.03%USDMXN-0.02%AUDNZD+0.02%AUDNOK+0.01%EURCZK+0.01%USDHKD+0.01%EURJPY+0.01%EURDKK0.00%COTTON+1.01%HG1+0.69%XNGUSD+0.44%S1+0.38%W1-0.28%UKOIL-0.23%USOIL-0.21%XPTUSD-0.18%GAGUSD-0.11%XAGUSD-0.11%GAUUSD-0.11%XAUUSD-0.11%BTCUSD+2.31%ETHUSD+17.67%USDTUSD+0.01%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.15%DOGEUSD+14.12%XMRUSDT+5.36%LINKUSD+13.42%XLMUSD-0.16%BCHUSDT+5.07%UNIUSD+7.17%LTCUSD+9.66%SUIUSD+3.01%HBARUSDT+0.10%TONUSD+26.15%TAOUSDT+3.23%AAVEUSD+3.21%DOTUSDT-0.54%ICPUSDT-0.05%ONDOUSDT+0.02%WLDUSDT-0.79%ARBUSDT+6.39%JUPUSDT+0.31%ATOMUSDT+1.07%INJUSDT+13.60%STXUSDT+6.52%FETUSDT+1.87%TIAUSDT+8.81%PYTHUSDT-0.57%SEIUSDT+4.57%IMXUSDT+0.06%OPUSDT+19.70%GRTUSDT+3.48%IOTAUSDT+0.35%WIFUSDT+2.21%AXSUSDT-1.83%POLUSDT+2.52%FARTCOINUSDT+0.44%EOSUSDT+1.66%DYDXUSDT+3.22%GALAUSDT-2.32%ORDIUSDT-0.40%RONINUSDT-3.42%NOTUSDT-1.01%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.62%GBPCHF+0.52%AUDCHF+0.43%GBPTRY+0.41%NZDCHF+0.41%USDCAD-0.40%EURCAD-0.35%GBPHKD+0.32%CADJPY+0.32%GBPUSD+0.31%GBPMXN-0.28%USDTRY+0.28%AUDSGD+0.27%CHFJPY-0.27%EURCHF+0.27%NZDSGD+0.25%NZDUSD+0.24%AUDUSD+0.23%GBPJPY+0.22%EURGBP-0.22%USDNOK-0.21%NZDCAD-0.20%USDCHF+0.20%GBPSGD+0.19%NZDMXN+0.18%AUDCAD-0.18%USDZAR-0.17%USDILS+0.16%EURSGD+0.16%USDPLN-0.16%USDSEK-0.16%CHFSGD+0.15%AUDJPY+0.15%NZDJPY+0.14%EURAUD-0.13%SGDJPY-0.13%NOKJPY+0.12%EURNZD-0.12%CHFNOK-0.11%AUDDKK+0.11%EURHKD+0.11%USDDKK-0.11%EURNOK-0.10%GBPAUD+0.09%USDTHB+0.09%GBPCAD-0.09%EURCNH+0.08%PLNJPY+0.08%EURUSD+0.07%USDJPY-0.07%GBPNZD+0.07%CHFSEK-0.06%EURZAR-0.06%USDSGD+0.05%EURPLN-0.05%EURSEK-0.05%USDCOP-0.04%GBPZAR-0.03%USDCNH-0.03%USDMXN-0.02%AUDNZD+0.02%AUDNOK+0.01%EURCZK+0.01%USDHKD+0.01%EURJPY+0.01%EURDKK0.00%COTTON+1.01%HG1+0.69%XNGUSD+0.44%S1+0.38%W1-0.28%UKOIL-0.23%USOIL-0.21%XPTUSD-0.18%GAGUSD-0.11%XAGUSD-0.11%GAUUSD-0.11%XAUUSD-0.11%BTCUSD+2.31%ETHUSD+17.67%USDTUSD+0.01%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.15%DOGEUSD+14.12%XMRUSDT+5.36%LINKUSD+13.42%XLMUSD-0.16%BCHUSDT+5.07%UNIUSD+7.17%LTCUSD+9.66%SUIUSD+3.01%HBARUSDT+0.10%TONUSD+26.15%TAOUSDT+3.23%AAVEUSD+3.21%DOTUSDT-0.54%ICPUSDT-0.05%ONDOUSDT+0.02%WLDUSDT-0.79%ARBUSDT+6.39%JUPUSDT+0.31%ATOMUSDT+1.07%INJUSDT+13.60%STXUSDT+6.52%FETUSDT+1.87%TIAUSDT+8.81%PYTHUSDT-0.57%SEIUSDT+4.57%IMXUSDT+0.06%OPUSDT+19.70%GRTUSDT+3.48%IOTAUSDT+0.35%WIFUSDT+2.21%AXSUSDT-1.83%POLUSDT+2.52%FARTCOINUSDT+0.44%EOSUSDT+1.66%DYDXUSDT+3.22%GALAUSDT-2.32%ORDIUSDT-0.40%RONINUSDT-3.42%NOTUSDT-1.01%
BI

Biohaven Ltd. (BHVN)

NYSE • Healthcare

$11.42
-$0.39 (-3.3%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$11.79
Day Range$11.16 - $11.79
Avg. Volume (3M)2.5M
Market Cap$1.7B
52 Week Range
$7.48$18.57
Next EarningsIn 26 daysNov 9, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$586.8M
EPS (TTM)
-$4.64
ROA (TTM)
-158.29%
Current Ratio
4.73

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+0.8%Q1 2026-$1.21
-2.3%Q2 2026-$0.88
-19.6%Q3 2026-$0.91
Next

Nov 9

in 26 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -19.6%

Biohaven Ltd. missed on EPS in the second fiscal quarter of 2026, with preliminary results reported on 2026-08-10 showing EPS of -$0.91 versus the -$0.76 estimate, a -19.6% miss. Gross profit was $0, operating income was negative about $124.9 million, and operating cash flow was negative $85.1 million. Net income came in at negative about $137.3 million, up 30.7% from negative $198.1 million a year ago, while EPS was up 53.1% from -$1.94.

Next report — what to expect

Biohaven Ltd. (BHVN) reports on November 9, 2026. Wall Street expects EPS of -$0.61 on revenue of $70.0 million. Recent history shows Biohaven has beaten EPS in 2 of 8 most recent quarters, so traders may focus on whether results align with those consensus targets and any shifts around revenue delivery.

View full earnings history

About Biohaven Ltd.

Biohaven Ltd. is a clinical-stage Biotechnology company listed on the NYSE under BHVN. The company develops drug candidates for disorders affecting the nervous and immune systems, placing it in the healthcare sector, and it remains in the trial stage rather than operating as a mature commercial pharmaceutical business.

Name
Biohaven Ltd.
CEO
Vladimir Coric
Website
www.biohaven.com
Industry
Healthcare
Employees
274

Today's Snapshot

AI-generated

BHVN closed 3.3% below yesterday's close, in line with a weaker sector. Biohaven agreed to a $100 million deal with Ono Pharmaceuticals, a Japanese drugmaker, to develop drugs that remove antibodies.

Trading Volume

Above 10d avg 1.9M

2M

vs S&P 500 Today

Strong Underperformance

-3.24%

Updated: October 13, 2026 at 20:15 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
BHVN’s chart favors the downside with clustered negative signals on momentum, breadth and volume. Price is under most short- and medium-term averages and below the 200-day level, while momentum shows an extended negative bias via CCI and MACD and RSI remains weak. ADX is middling, not signaling a powerful trend but enough to confirm recent weakness, and ATR is elevated, reflecting larger intraday moves. OBV is negative, indicating net outflows and the classic pivot is above the market. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$12.24 - $13.39
    Sell
  • RSI (14)34.29
    Neutral
  • Stochastic %K (14, 3, 3)12.85
    Buy
  • MACD Level (12, 26)-0.62
    Sell

Peers & Related Assets

VERAVera Therapeutics, Inc.
$26.79-3.4%
CLDXCelldex Therapeutics, Inc.
$28.25-4.0%
XERSXeris Biopharma Holdings, Inc.
$10.2-2.5%
IMNMImmunome, Inc.
$17.58-8.2%
NTLAIntellia Therapeutics, Inc.
$11.91-5.3%
ZBIOZenas BioPharma, Inc.
$25.16-4.7%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.